Application of GRP75 inhibitor for preparing medicine for treating age-related macular degeneration

Drugs made using GRP75 inhibitors address the problem of retinal pigment epithelial cell damage in dry age-related macular degeneration, significantly improving cell viability and retinal pathology, and have the potential to treat dry AMD.

CN118949032APending Publication Date: 2024-11-15WUXI PEOPLES HOSPITAL
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202410880504.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-02
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Currently, there is a lack of effective treatments for dry age-related macular degeneration, especially for vision loss caused by damage to retinal pigment epithelial cells. Existing techniques, such as intravitreal injection of anti-VEGF drugs, are only effective for wet AMD.

Method used

Using a GRP75 inhibitor as the active ingredient, the drug is formulated into a pharmaceutical form via a pharmaceutically acceptable carrier for the treatment of dry age-related macular degeneration.

Benefits of technology

GRP75 inhibitors significantly enhance the viability of retinal pigment epithelial cells in cell and animal experiments, improve the retinal pathological features of dry AMD, and protect the retinal pigment epithelium, showing promise for development into therapeutic drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949032A_ABST
    Figure CN118949032A_ABST
Patent Text Reader

Abstract

The invention discloses application of a GRP75 inhibitor to preparation of a medicine for treating age-related macular degeneration. The cell level experiment shows that the GRP75 inhibitor can effectively improve the cell activity of retinal pigment epithelial cells in the dry age-related macular degeneration; animal level experiments show that the GRP75 inhibitor can effectively improve retinal pathological characteristics in dry age-related macular degeneration and effectively protect the retinal pigment epithelium. By integrating cell level and animal level experiments, the GRP75 inhibitor has the application prospect of being developed into the medicine for treating the dry age-related macular degeneration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to the use of a GRP75 inhibitor for preparing a drug for treating age-related macular degeneration. Background Art

[0002] Age-related macular degeneration (AMD) is a retinal degenerative disease that causes progressive loss of central vision in the elderly. Based on the clinical manifestations of AMD patients, AMD is divided into two categories: wet (exudative) and dry (non-exudative), of which dry AMD patients account for 80% of all AMD patients. Wet AMD is characterized by choroidal neovascularization (CNV), while dry AMD initially manifests as accumulation of drusen and slowly progresses to geographic atrophy.

[0003] Currently, intravitreal injection of anti-VEGF drugs has been shown to effectively alleviate wet AMD, but there is still a lack of effective treatment for dry AMD. Geographic atrophy of the retinal pigment epithelium is a typical manifestation of AMD, and damage to the retinal pigment epithelium (RPE) is an important pathogenesis, but the mechanism of RPE damage is still unclear.

[0004] There are currently no reports on the association of glucose-regulated protein 75 (GRP75) with AMD treatment. Summary of the invention

[0005] The present invention aims to provide use of a GRP75 inhibitor for preparing a drug for treating age-related macular degeneration.

[0006] The above-mentioned purpose of the present invention is achieved through the following technical solutions:

[0007] A use of a GRP75 inhibitor for preparing a drug for treating age-related macular degeneration.

[0008] Preferably, the age-related macular degeneration is dry age-related macular degeneration.

[0009] More preferably, the drug uses a GRP75 inhibitor as an active ingredient and is prepared into a pharmaceutically acceptable dosage form using a pharmaceutically acceptable carrier or excipient.

[0010] Beneficial effects:

[0011] 1. The present invention shows through experiments at the cell level that GRP75 inhibitors can effectively improve the cell viability of retinal pigment epithelial cells in dry age-related macular degeneration;

[0012] 2. The present invention has shown through animal experiments that GRP75 inhibitors can effectively improve retinal pathological features in dry age-related macular degeneration and effectively protect the retinal pigment epithelium;

[0013] 3. Based on experiments at the cellular and animal levels, GRP75 inhibitors have the potential to be developed into drugs for the treatment of dry age-related macular degeneration. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 Induce high expression of GRP75 for in vitro model of dry AMD;

[0015] Figure 2 GRP75 siRNA significantly reduced the expression of GRP75 in ARPE-19 cells;

[0016] Figure 3 Silencing GRP75 improves the survival rate of ARPE-19 cells;

[0017] Figure 4 AAV8-shGRP75 significantly reduced the expression of GRP75 in the retina of dry AMD mice;

[0018] Figure 5 To silence GRP75 to improve the retinal pathological changes in dry AMD mice;

[0019] Figure 6 Silencing GRP75 improves retinal morphological abnormalities in dry AMD mice;

[0020] Figure 7 Silencing GRP75 inhibits the downregulation of RPE65 protein in the retina of dry AMD mice. DETAILED DESCRIPTION

[0021] The essential contents of the present invention are described in detail below in conjunction with the embodiments, but the protection scope of the present invention is not limited thereto.

[0022] Example 1: Cellular level

[0023] 1. Experimental Materials

[0024] 1. Cells

[0025] Human retinal pigment epithelial cells (ARPE-19) were purchased from Bluefbio Biology Technology (Shanghai, China) and cultured in DMEM medium (Gibco, USA) supplemented with 10% FBS and double antibodies.

[0026] 2. Experimental instruments and equipment

[0027] instrument Purchased Company Carbon dioxide incubator Thermo Electric constant temperature water bath Changfeng Company Ultrapure water machine Pall Life Sciences Low temperature high speed centrifuge eppendorf -80℃ Refrigerator Thermo Liquid nitrogen tank Leshan Dongya Electromechanical Industry and Trade Company Ice Maker Scotsman Fluorescence inverted microscope Olympus Laser confocal microscopy Lecia

[0028] 3. Experimental reagents and consumables

[0029]

[0030]

[0031] 2. Experimental Methods

[0032] 1. Cell modeling

[0033] When the ARPE-19 cell confluence reached 80%, sodium iodate (NaIO 3 , 10 mM) for 24 hours to simulate dry AMD in vitro. The expression level of GRP75 protein was detected by Western blot.

[0034] 2. Cell gene knockdown

[0035] When the confluency of ARPE-19 cells reached 60-80%, GRP75 siRNA was transfected into ARPE-19 cells using the riboFECT CP transfection kit according to the instructions. 120μL Opti-MEM medium was pre-mixed with 12μL riboFECT CP, 100nM GRP75 siRNA or 100nM NC, and added to the cell culture plate after standing at room temperature for 15 minutes. Western blot was used to verify the knockout efficiency 48 hours after cell transfection. Detailed information of siRNA is shown in the table below.

[0036] name sequence si-h-GRP75-1(siGRP75-1) GCGATATGATGATCCTGAA si-h-GRP75-2 (siGRP75-2) GAGTCAGATTGGAGCATTT si-h-GRP75-3 (siGRP75-3) GCTGGAATGGCCTTAGTCA NC-siRNA GGCTCTAGAAAAGCCTATGC

[0037] 3. CCK-8 detection

[0038] ARPE-19 cells with good growth status were seeded in 96-well plates and transfected with si-h-GRP75-3 (siGRP75) or NC-siRNA (siCON, NC) for 24 hours. 3 Incubate for 24 hours, and set up a control group (CON) and a model group (Vehicle, modeling without transfection). Discard the culture medium, add 100 μL of the prepared CCK-8 mixture to each well, and incubate at 37°C, 5% CO 2 Incubate in an incubator for 1 hour. Measure the absorbance (OD value) at 450 nm using an enzyme-labeled instrument to assess cell viability.

[0039] 4. Statistical analysis

[0040] All data are expressed as the mean ± SD of 3 independent experiments. Statistical analysis was performed using GraphPad Prism version 9.0 software using one-way ANOVA with Tukey's honestly significant difference test. P < 0.05 was considered statistically significant.

[0041] 3. Experimental Results

[0042] like Figure 1 As shown, NaIO 3 After modeling dry AMD, it was found that the expression level of GRP75 was significantly increased.

[0043] Cell gene knockdown results Figure 2 As shown in the figure, si-h-GRP75-1, si-h-GRP75-2, and si-h-GRP75-3 can effectively inhibit the expression of GRP75. We selected si-h-GRP75-3 with the highest knockdown efficiency for subsequent experiments.

[0044] CCK-8 test results Figure 3 As shown in the figure, compared with the control group, the cell viability of the model group was significantly reduced, indicating that the model was successfully established; compared with the model group, the cell viability of the siGRP75 group was significantly increased, indicating that inhibition of GRP75 can effectively improve the cell viability of human retinal pigment epithelial cells in the dry AMD model. The cell viability of the transfected control NC group was not significantly improved.

[0045] The above-mentioned experiments at the cellular level showed that GRP75 inhibitors can effectively increase the cell viability of retinal pigment epithelial cells in dry age-related macular degeneration.

[0046] Example 2: Animal Level

[0047] 1. Experimental Materials

[0048] 1. Experimental Animals

[0049] Male C57BL / 6J mice (6-8 weeks, 20-22 g, Changzhou Cavens Laboratory Animal Co., Ltd., Changzhou, China) were housed under standard conditions and randomly assigned to 6-8 mice per cage. After one week of adaptive feeding, they were used for experiments.

[0050] 2. Experimental instruments and equipment

[0051] instrument Purchased Company Ultrapure water machine Pall Life Sciences Low temperature high speed centrifuge eppendorf -80℃ Refrigerator Thermo Ice Maker Scotsman Fluorescence inverted microscope Olympus Laser confocal microscopy Lecia Paraffin slicer Thermo Cryostat Thermo Stereo dissecting microscope Zeiss Small Animal Retinal Ultra-Wide Angle Imaging System TowardPi

[0052] 3. Experimental reagents and consumables

[0053] Reagents Purchased Company <![CDATA[Sodium iodate (NaIO 3 )]]> Sigma Anti-Fluorescence Quenching Agent Shanghai Bio-Tech Biotechnology Co., Ltd. Eye fixative Wuhan Google Sewell Biotech OCT cryosection embedding medium SAKURA DAPI ThermoFisher TritonX-100 Biosharp ZO-1 antibody abcam GRP75 Antibody Santa

[0054] 2. Experimental Methods

[0055] 1. Grouping, modeling and drug administration

[0056] Adeno-associated virus serotype 8 (AAV8) targeting RNA silencing of GRP75 (AAV8-shGRP75) was constructed and packaged. The sequence information of AAV8-shGRP75 is shown in the table below. Sixty 6-8 week old male C57BL / 6J mice were randomly divided into 4 groups (n=15) after 1 week of adaptive feeding: control group (Ctrl), NaIO 3 Group (model group, Vehicle), NaIO 3 +AAV8-vector group (AAV8-NC) and NaIO 3 +AAV8-GRP75 group (AAV8-GRP75). Control group and NaIO 3 The AAV8-vector group was injected with 2 μL PBS solution into the vitreous cavity, the AAV8-vector group was injected with 2 μL AAV8-vector into the vitreous cavity, and the AAV8-shGRP75 group was injected with AAV8-shGRP75 (6×10 12 viral genomes / mL).

[0057] Two weeks after the injection of adeno-associated virus, the control group was injected with an equal volume of normal saline, and the other groups were injected with NaIO 3 (50mg / kg) to induce dry AMD.

[0058] name sequence GRP75-shRNA (mouse) GAGGCGTCTTTACCAAACTTA NCshRNA(mouse) TTCTCCGAACGTGTCACGT

[0059] 2. Mouse retinal OCT (SS-OCT) and SS-OCTA imaging

[0060] Tail vein injection of NaIO 3 After 7 days, in vivo retinal OCT (SS-OCT) and SS-OCTA imaging of mice were performed. Mice were placed on a fixator after intraperitoneal anesthesia, and the structure of the mouse retina was observed using SS-OCT and SS-OCTA (TowardPi BMizar, TowardPi Medical Technology, Beijing, China). The SS-OCT / SS-OCTA system has an axial scanning depth (6 mm), B-scan length (24 mm), and axial optical resolution (3.8 μm). The OCTA imaging range is 24 mm × 20 mm, which is equivalent to an imaging range of 120 degrees in the central field of view, so high-resolution fundus images can be obtained. B-scan OCT images of mice were acquired using SS-OCT, and RPE layer images were acquired in SS-OCTA en face mode. All data were acquired and exported using the instrument's integrated software.

[0061] 3. Western blot detection

[0062] Tail vein injection of NaIO 3 After 7 days, the mouse retinas were collected, and the retinal tissue proteins were extracted at low temperature and then Western blot was performed. The specific steps of Western blot are as follows:

[0063] (1) Prepare 10% or 12% SDS / PAGE electrophoresis gel: clean the glass plate, assemble it, pour in ultrapure water to check for leaks, and prepare the gel at the same time. Prepare the lower gel first, then the upper gel. Mix the other gel preparation reagents first, pour out the ultrapure water used for leak testing, absorb dry, add TEMED to the lower gel, turn the 50mL centrifuge tube upside down to mix, slowly add it to the glass plate with a pipette, press the gel with ultrapure water, and let it stand at room temperature for 30 minutes; discard the ultrapure water used for pressing the gel, add TEMED to the upper gel, mix well, add it to the glass plate, insert a comb, and let it stand at room temperature for 30 minutes to solidify.

[0064] (2) Loading: Take out the protein sample, wait for it to melt, vortex for a few seconds, and centrifuge; install the gel, pour in the prepared electrophoresis solution to cover the glass plate, pull out the comb, and add the marker and protein sample.

[0065] (3) Electrophoresis: Perform electrophoresis at 60 V. When the sample is electrophoresed to the bottom of the concentrated gel and a red marker appears, adjust the voltage to 100 V and continue electrophoresis to the bottom of the separation gel.

[0066] (4) Transfer: After electrophoresis, activate the PVDF membrane with methanol for 3 minutes, then soak the PVDF membrane, gel, sponge, and filter paper in the transfer solution, and clamp each part in order and load it into the transfer clamp: black sponge - filter paper - SDS-PAGE gel - PVDF membrane - filter paper - black sponge. After installation, clamp it tightly and put it into the tank, inject pre-cooled transfer solution, and transfer the membrane at a constant current of 300mA. Set the time according to the molecular weight of the target protein.

[0067] (5) Blocking: Immerse the membrane in 5% skim milk, shake it slowly on a shaker, and block it at room temperature for 1.5-2 hours.

[0068] (6) Incubation with primary antibodies: The blocked membrane was washed three times with TBST, each time for 5 minutes; primary antibodies: GRP75 (1:200) and β-actin (1:5000) were added, and the membrane was slowly shaken on a shaker at 4°C overnight.

[0069] (7) Incubation with secondary antibody: On the second day, wash three times with TBST on a shaker at 85-90 rpm for 5 minutes each time. Add secondary antibody and incubate at room temperature for 2 hours with slow shaking on a shaker. Wash three times with TBST for 5 minutes each time.

[0070] (8) Exposure: ECL luminescent solution was prepared in a 1:1 (A:B) ratio, and the membrane was placed in a developer for exposure. The grayscale value of the bands was analyzed using Image J software and the results were statistically analyzed.

[0071] 4. Retinal RPE layer plank

[0072] Tail vein injection of NaIO 3 After 7 days, the mouse eyeball tissue was collected, and the cornea, lens, optic nerve and surrounding myofascial tissue were removed and fixed with 4% paraformaldehyde. After PBS washing, the tissue was incubated with ZO-1 (1:200) antibody at 4°C overnight. The tissue was trimmed into a four-leaf clover shape on a slide and incubated with AlexaFluor 488 goat anti-rabbit antibody (1:400) at room temperature for 2 hours. After PBS washing, the tissue samples were stained with DAPI for 15 minutes, and images were collected using a laser scanning confocal microscope (20×).

[0073] 5. Immunofluorescence (IF)

[0074] Tail vein injection of NaIO 3 After 7 days, the mouse eyeball tissue was collected, the cornea was separated, and the retinal tissue was fixed in the eyeball fixative overnight, and then placed in 30% sucrose for dehydration. After dehydration, the tissue was embedded in OCT embedding medium and quickly frozen in liquid nitrogen. The OCT-embedded tissue was cut into 8μm frozen sections and immunofluorescence staining was performed. The staining method is as follows:

[0075] After the frozen sections returned to room temperature, they were washed three times with PBS for 5 minutes each time; permeabilized with 0.5% Triton X-100 for 30 minutes and blocked with cell blocking solution at 37°C for 1.5 hours. The samples were incubated with RPE65 (1:100) antibody at 4°C overnight. On the second day, after the slides returned to room temperature, they were incubated with Alexa488 / 555 (1:400) labeled fluorescent secondary antibodies in the dark for 2 hours and washed with PBS three times for 5 minutes each time. The cell nuclei were stained with DAPI (1:500) for 15 minutes. Fluorescence was detected and images were collected using a laser scanning confocal microscope (20×, Leica, Germany).

[0076] 6. Statistical analysis

[0077] All data are expressed as the mean ± SD of 3 independent experiments. Statistical analysis was performed using GraphPad Prism version 9.0 software using one-way ANOVA with Tukey's honestly significant difference test. P < 0.05 was considered statistically significant.

[0078] 3. Experimental Results

[0079] 1. Western blot test results

[0080] Western blot test results Figure 4 As shown in the figure, compared with the control group, the expression level of GRP75 protein in the model group was significantly upregulated; compared with the model group, the expression level of GRP75 protein in the AAV8-GRP75 group was significantly downregulated, indicating that the constructed AAV8-shGRP75 played the expected role in knocking down GRP75. No significant downregulation of GRP75 protein expression was observed in the vector control AAV8-NC group.

[0081] 2. Typical retinal OCT and ultra-wide-angle en-face imaging results

[0082] like Figure 5 The number of punctate high-reflection signals on the retina of mice in the model group and AAV8-NC vector group increased, and the outer nuclear layer became thinner, while the above pathological manifestations of the retina of mice in the AAV8-shGRP75 group were significantly improved.

[0083] 3. Results of retinal RPE layer flat mount

[0084] Zonal adhesion protein 1 (ZO-1) is a characteristic indicator of the barrier function of RPE cells, and decreased barrier function of the pigment epithelium is a typical ocular manifestation of AMD lesions. Figure 6 Immunofluorescence staining showed that the tight junction function of the retinal RPE layer of mice in the NaIO3 group and the AAV8-NC vector group was destroyed, while knocking down GRP75 improved the above pathological changes.

[0085] 4. Immunofluorescence (IF) results

[0086] RPE65 protein is involved in retinal pigment regeneration. The level of retinal pigment regeneration can be known by detecting the expression level of RPE65 protein, which is an important manifestation of AMD progression. Figure 7 It can be seen that compared with the control group, the expression level of RPE65 protein in the model group was significantly downregulated, indicating that the level of retinal pigment regeneration in the model group was decreased; compared with the model group, the expression level of RPE65 protein in the AAV8-GRP75 group was significantly upregulated, indicating that knocking down GRP75 improved the level of retinal pigment regeneration. No significant increase in the expression level of RPE65 protein was observed in the vector control AAV8-NC group.

[0087] The above-mentioned animal level experiments showed that GRP75 inhibitors can effectively improve retinal pathological characteristics in dry age-related macular degeneration and effectively protect the retinal pigment epithelium.

[0088] Based on experiments at the cellular and animal levels, GRP75 inhibitors have the potential to be developed into drugs for the treatment of dry age-related macular degeneration.

[0089] The purpose of the above-mentioned embodiments is to specifically introduce the essential content of the present invention, but those skilled in the art should know that the protection scope of the present invention should not be limited to the specific embodiments.

Claims

1. Use of a GRP75 inhibitor for preparing a drug for treating age-related macular degeneration.

2. The use according to claim 1, wherein the age-related macular degeneration is dry age-related macular degeneration.

3. The use according to claim 1 or 2, wherein the drug has a GRP75 inhibitor as an active ingredient and is prepared into a pharmaceutically acceptable dosage form using a pharmaceutically acceptable carrier or excipient.

Citation Information

Cited By

  • Application of RBM15 inhibitor in medicine for treating dry age-related macular degeneration

    CN120000797A

  • Application of DKK1 inhibitor in preparation of medicine for treating dry age-related macular degeneration

    CN120158507A

  • Use of a dkk1 inhibitor in the manufacture of a medicament for treating dry age-related macular degeneration

    CN120158507B